Kronos Bio (KRON) Competitors

Kronos Bio (NASDAQ:KRON) and Genfit (NASDAQ:GNFT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, media sentiment, profitability, institutional ownership, community ranking, valuation and earnings.

Does the media refer more to KRON or GNFT?

In the previous week, Kronos Bio and Kronos Bio both had 1 articles in the media. Genfit's average media sentiment score of 0.50 beat Kronos Bio's score of 0.47 indicating that Genfit is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kronos Bio	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Genfit	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more volatility and risk, KRON or GNFT?

Kronos Bio has a beta of 1.87, suggesting that its stock price is 87% more volatile than the S&P 500. Comparatively, Genfit has a beta of 1.22, suggesting that its stock price is 22% more volatile than the S&P 500.

Do insiders & institutionals believe in KRON or GNFT?

64.1% of Kronos Bio shares are owned by institutional investors. Comparatively, 2.2% of Genfit shares are owned by institutional investors. 23.4% of Kronos Bio shares are owned by insiders. Comparatively, 4.2% of Genfit shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Is KRON or GNFT more profitable?

Genfit has a net margin of 0.00% compared to Kronos Bio's net margin of -1,222.83%. Genfit's return on equity of 0.00% beat Kronos Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kronos Bio	-1,222.83%	-68.82%	-51.52%
Genfit	N/A	N/A	N/A

Which has higher earnings and valuation, KRON or GNFT?

Genfit has higher revenue and earnings than Kronos Bio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kronos Bio	$8.41M	6.77	-$112.67M	-$1.99	-0.48
Genfit	$28.57M	7.32	-$31.27M	N/A	N/A

Do analysts recommend KRON or GNFT?

Kronos Bio presently has a consensus target price of $4.13, indicating a potential upside of 335.31%. Genfit has a consensus target price of $13.00, indicating a potential upside of 210.26%. Given Kronos Bio's higher possible upside, research analysts clearly believe Kronos Bio is more favorable than Genfit.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kronos Bio	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Genfit	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the MarketBeat Community prefer KRON or GNFT?

Genfit received 46 more outperform votes than Kronos Bio when rated by MarketBeat users. However, 68.97% of users gave Kronos Bio an outperform vote while only 68.75% of users gave Genfit an outperform vote.

Company	Underperform	Outperform
Kronos Bio	Outperform Votes 20 68.97%	Underperform Votes 9 31.03%
Genfit	Outperform Votes 66 68.75%	Underperform Votes 30 31.25%

Summary

Genfit beats Kronos Bio on 8 of the 14 factors compared between the two stocks.